The Rationale for and Clinical Pharmacology of Prasugrel 5 mg.

Published

Journal Article (Review)

Prasugrel is a third-generation thienopyridine platelet P2Y12 adenosine diphosphate (ADP) receptor antagonist administered with aspirin for the treatment of patients with acute coronary syndrome (ACS) with planned percutaneous coronary intervention. Prasugrel is administered periprocedurally at an oral loading dose of 60 mg followed by daily maintenance doses (MDs) of 10 mg for most patients and 5 mg for patients weighing <60 kg or aged ≥75 years. Data from a prasugrel phase III study, TRITON-TIMI 38, suggested that a lower MD might be more suitable for patients weighing <60 kg or aged ≥75 years; subsequent pharmacokinetic and pharmacodynamic studies have indicated that prasugrel 5 mg reduced platelet reactivity in these populations to an extent similar to that of prasugrel 10 mg in heavier or younger patients. Clinical experience with prasugrel 5 mg is limited, and additional studies are needed to verify the clinical efficacy and safety of this dose in these challenging populations.

Full Text

Duke Authors

Cited Authors

  • Jakubowski, JA; Erlinge, D; Alexopoulos, D; Small, DS; Winters, KJ; Gurbel, PA; Angiolillo, DJ

Published Date

  • April 2017

Published In

Volume / Issue

  • 17 / 2

Start / End Page

  • 109 - 121

PubMed ID

  • 27854064

Pubmed Central ID

  • 27854064

Electronic International Standard Serial Number (EISSN)

  • 1179-187X

Digital Object Identifier (DOI)

  • 10.1007/s40256-016-0202-3

Language

  • eng

Conference Location

  • New Zealand